Melissa Hackel - Infinity Pharmaceuticals Insider

INFI -- USA Stock  

USD 1.76  0.29  14.15%

Vice President - Finance

Ms. Melissa Hackel serves as Vice President Finance of the Company. Melissa Hackel joined Infinity in 2015 and has more than 15 years of financial experience in the pharmaceutical and medical device industry and has made financial and operational contributions throughout her career leading and developing teams to manage financial analysis in support of strategic decisionmaking. Prior to joining Infinity, Ms. Hackel served as director of finance at Takeda Pharmaceutical Company. She received a MBA from Duke University and a B.A. in political science from Bates College.
  President Since 2017  MBA    
617-453-1000  http://www.infi.com

Management Efficiency

The company has return on total asset (ROA) of (28.88) % which means that it has lost $28.88 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (68.47) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 22 people.Infinity Pharmaceuticals (INFI) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 22 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Infinity Pharmaceuticals Leadership Team

Joseph Pearlberg, President, Ph.D
Melissa Hackel, President, MBA
William Bertrand, President
Vito Palombella, EVP
Jeffrey Berkowitz, Director
Lawrence Bloch, President, MBA
Norman Selby, Director, MBA
Jose Baselga, Director, Ph.D
Michael Venuti, Director, Ph.D
Michael Kauffman, Director
Eric Lander, Director, Ph.D
David Beier, Director
Julian Adams, President
Anthony Evnin, Director, Ph.D
Gwendolyn Fyfe, Director
Sujay Kango, President, MBA
Ian Smith, Director
Adelene Perkins, Chairman, MBA

Stock Performance Indicators

Did you try this?

Run Premium Stories Now
   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Premium Stories

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.